| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/FON-2017-0170 |
| P698 | PubMed publication ID | 28587477 |
| P50 | author | Reinhard Dummer | Q32650033 |
| P2093 | author name string | Peter Koelblinger | |
| Joelle Dornbierer | |||
| P2860 | cites work | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy | Q26769870 | ||
| Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis | Q27851617 | ||
| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. | Q27851801 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma | Q34633455 | ||
| Genomic Classification of Cutaneous Melanoma | Q34670776 | ||
| Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma | Q35621653 | ||
| Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival? | Q35794989 | ||
| Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms | Q36338753 | ||
| Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas | Q37028299 | ||
| Searching for the Chokehold of NRAS Mutant Melanoma. | Q37038604 | ||
| A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor | Q37691482 | ||
| MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade | Q38788877 | ||
| Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. | Q39174229 | ||
| Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016. | Q40671706 | ||
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Q40875359 | ||
| Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology | Q54348570 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1755-1766 | |
| P577 | publication date | 2017-06-07 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | A review of binimetinib for the treatment of mutant cutaneous melanoma | |
| P478 | volume | 13 |
| Q47550452 | Development of encorafenib for BRAF-mutated advanced melanoma |
| Q60302150 | Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy |
| Q91584750 | Prognostic genes of melanoma identified by weighted gene co-expression network analysis and drug repositioning using a network-based method |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q64987698 | Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. |
Search more.